quinolones  18 

 


  !"#$"

% Antibiotic and vaccine use in special circumstances

     ! " 
# $%& '
epiphyseal plate ( ')*)&+1 &)$("( )'  ,! ("$%
) 18 /0 $%
epiphyseal plate /1!2 /1   2%'("  ("/3!  ! + 
&&4()/) ')*)&+ +4$" !2#4$%%#2% 5
  4()/)#&&/$  6$%  4()/)# "+4
prolong QT syndrome 4()/)#& (2% 
/7''
& $',/8 
  
 18 /0 &9#  2 +
!
( !  3 /42 1) 2! $%" :
 $%2+4 2) ;
:  )&/$  )2% $ $  3) ! !2
2%
4+4)2  !/$$'&9 '$,# /8 4,  ,2%! $
,/;" /<)&)
&'!
(

1
2
3
4
5

!/= )2! (+4   Bacillus

anthracis +"  meningococcal infection
)2$) /7'2 P. aeruginosa !2
mutidrug-resistant gram negative bacteria
+4 chronic suppurative otitis media !2 malignant otitis
externa '2 P. aeruginosa
+4 chronic !2 acute osteomyelitis/osteochondritis '
2 P. aeruginosa
Exacerbation  ("/3+4/2  cystic fibrosis $%
P. aeruginosa /8 colonization ; &&("/3


%)*&! +,-
"(.
*/%&'!
(
(+,'

 ,'0',&'!
((
5A  1A
2A
4C
5C
2B

+4)2 mycobacteria $%2! 2% 5 4!2

$& 
 
7 ("/3$%6")4
 &)2 &4$ &$%
&/$ !222%
8 +4)2$) !!
' multidrug-resistant
Shigella spp., Salmonella spp., Vibrio cholerae !2
Campylobacter jejuni
9 +4 bacterial septicemia !2 meningitis '2$%2
2% !2)>$?)@( ! 2% 2%',/8 !2
("/3$%6")4
 &$%:2% (
10 +4)2
'2$%  $% !  

2% 5

11 ("/3 febrile neutropenia $% 
 beta-lactam 


12 +4)22% 5 $%;/<)  )2% 
/)$?)6 !2/ 6 !2',/8 
&/$

5C
2B
3B

5C

5C
1B
5C

%)*  ,&! +,-"(.

*/% (Level of Evidence)
,'"(. 1 ! A $%' )'$%/8 randomized controlled trials !2 systematic review $%
  1  )'
,'"(. 2 ! A $%' )'$%/8 non-randomized controlled trials !2 before & after
clinical trials !2 cohort studies
,'"(. 3 ! A $%'$%/8 case-control studies
,'"(. 4 ! A $%'$%/8 descriptive, case report !2 case series
,'"(. 5 ! A $%/8 expert opinion !2 : $) (consensus) #49("%*
,'
 ,'0', (Grade of Recommendation)
,' A $/<)&) ! ,/ (strongly recommended)
,' B $/<)&) ! ,/ (recomended)
,' C $/<)&) /8 $ 2! %  ,/ (optional)

,' D $/<)&)   ,! ,/ 9$%/ (Not recommended in normal situation)
,' E $/<)& )   ,! ,/ (NOT recommended in all situations)
+(
1. #" '/)$?)6#$%/= +4! ('2 anthrax $%/8 clinical
controlled trial ',  2%'/8 +4
!;$,/&$&&! 
Anthrax /8 +4$%4
 /8 
?6  49!
#/$!A) (US FDA) " 4&4
 /= +4)#/$
!A) (Centers for Disease Control and Prevention, CDC) '/#  ,3-6 !/= +4
anthrax ! (+"+ ciprofloxacin #  10-15 ././+H &/$ $
12
%+ # "
) 1 / /8   60  +  ,!/8 $% &2 ' '
$&( 4#/<) 2
Meningococcal disease /8 +4$%4
  ' CDC  ,!/=
! (:9( && ) (close contact)7 $    " &  &("/3
&
4 $%$!'+42%/= $%! ("/3'&/<) ; 24
%+ (("/36 7    9/   ;     !&
("/3 ()%4! %+ '"&  /M7 !2  /<) $%  ,! 
rifampin, ceftriaxone, azithromycin !2 ciprofloxacin ,!& ciprofloxacin ')'9 

  1 2 # / #  20 ./. &/$ 4 # "

) 500 .7-9
2.  2%'
 quinolone   ciprofloxacin /8 $%>$?)@ P2 P. aeruginosa '
/8 $ 2 )2$) /7 (UTI) $%!
' P. aeruginosa !2
multidrug-resistant gram negative bacteria )'9 , 2%' ciprofloxacin /8 &/$
$% bioavailability "  !*#&$/7 ( #4  '/8 $%! 
)2$) /7 #" 
 quinolone )2$) /7
', &( $4 ) )10-12 $% !!   quinolone Q% 
ciprofloxacin /)$?)6 )2$) /7'2 P. aeroginosa !2
multidrug-resistant gram negative bacteria
 )&/$ $%"Q ciprofloxacin ("Q  70)13 4&/$
& magnesium-  aluminum-containing acids, sucralfate ( aluminum) !2 ferrous sulfate14
3. '( $4 ) )15,16 & ciprofloxacin ear drop /)$?)6  chronic
suppurative otitis media Q%2+4 !*  S. aureus  P. aeruginosa )'9 systemic
3

ciprofloxacin   chronic suppurative otitis media '2 P. aeruginosa Q%;+
&! $%" !" (aural toilet) !2;:$% (topical therapy) 

4. $4 ) ) & quinolone +: ciprofloxacin /)$?)6 )2
#" #+:2 P. aeruginosa &'##"" # &"
&4 #( !! "/&/$ !2:#  217,18 
!*/8  ("!*   ', 4)'9!4!
5. #" /)$?)6# ciprofloxacin  "/&/$ )2 P. aeruginosa  /
#("/3 cystic fibrosis # & $,!)2# ;  9810019-22 '&)2Q,  47-7419-22
6. 
 quinolone '/8 second-line drug #9+4 & moxifloxacin23,24 >$?)@
 P2 Mycobacterium tuberculosis $%
+& MIC 2%,   

fluoroquinolone +: levofloxacin, moxifloxacin '/8 $%&$&$,4* 9+4$%2
 (multidrug-resistant tuberculosis)25  ofloxacin /8 $%#" $4 ) ) ("/3
$%/8 9+426
7. )2 &4$ &$%
 quinolone 2$$%/8 )2 
 )
2 +& (4( '4#2) $$%/8 intracellular organism 
salmonella ;#Q   22%27  extracellular organism  E. coli $%

&)92 )%# ;  5028 2% 5  aminoglycoside, cephalosporin
8. 2%/&$& 3  )
 quinolone $%  ! 42 norfloxacin, ofloxacin
 ciprofloxacin 4
9&)6)$$%,4*&/ $% $4$&2% ,//&$
4 ) )  $% 214,29

$% 2 4
9&)$6)$&/# norfloxacin, ofloxacin  ciprofloxacin

norfloxacin
ofloxacin
ciprofloxacin

"/ &&
tablet
tablet
tablet, iv

bioavailability (%)
50
 95
70

#&;$
(%)
27
73
29

( 2%!

(
(
(

 norfloxacin ;""Q '$) !   '" lumen # ,/8 
!* !$%'+4$ 2%#&;$/7'" /7'
;+4)2$) /7   /7& (cystitis) !2$
/7& (urethritis)   2%'"Q '4 ,/+4&
(acute pyelonephritis) 4 2/8 ofloxacin !2 ciprofloxacin $ '
,!&+4)2$) !4!/<) 
 quinolone  5 $%  ,
42 norfloxacin #  15-20 ././ &!  2 4 /8   3 
9. +4 bacterial septicemia !2 meningitis '2$%22% !2'!( '! &&
combination 2%)>$?)@( ! 2%   Pseudomonas aeruginosa, Klebsiella
pneumoniae30-32
92%!
&'2 Salmonella spp. )'9!: && combination !
cefotaxime/ceftriaxone & ciprofloxacin /8   4-6 /!33
10. Quinolone )  && hypersensitivity type I (anaphylaxis)   2% ! %
 

 !) 34,35 &  cross reaction &
2%
11. 9("/3 febrile neutropenia $% 
 beta-lactam 
 ')'9 ciprofloxacin
& clindamycin /8 &2 4&4
 (empirical treatment)  36
12. +4)22% 5 $%;/<) 2% /)$?)6 !2/ 6 (
922 !2 ) !2',/8 &/$ +2% $%&/$ 
/)$?)6

!!
1. Schaad UB, Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am. 2005;
19:617-28.
2. Committee on Infectious Diseases. The use of systemic fluoroquinolones.
Pediatrics. 2006;118:1287-92.
3. Centers for Disease Control and Prevention (CDC). Update: Investigation of anthrax associated
with intentional exposure and interim public health guidelines, October 2001. MMWR Morb
Mortal Wkly Rep. 2001;50:889-93.
4. Centers for Disease Control and Prevention (CDC). Recognition of illness associated with the
intentional release of a biologic agent. MMWR Morb Mortal Wkly Rep. 2001;50:893-7.
5. Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related
anthrax and interim guidelines for exposure management and antimicrobial therapy, October
2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-19.
6. Meyerhoff A, Albrecht R, Meyer JM, Dionne P, Higgins K, Murphy D. US Food and Drug
Administration approval of ciprofloxacin hydrochloride for management of postexposure
inhalational anthrax. Clin Infect Dis. 2004;39:303-8.
7. American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, Baker CJ,
Kimberlin DW, Long SS, eds. Red Book 2009: Report of the Committee on Infectious Diseases.
28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:455-63.
8. Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal
infections. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004785.
9. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med.
2006;355:1466-73.
10. van den Oever HL, Versteegh FG, Thewessen EA, van den Anker JN, Mouton JW, Neijens HJ.
Ciprofloxacin in preterm neonates: case report and review of the literature. Eur J Pediatr.
1998;157:843-5.
11. Naccari F, Salpietro DC, De Sarro A, et al. Tolerance and pharmacokinetics of ciprofloxacin in
the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI).
Res Commun Mol Pathol Pharmacol. 1998;99:187-92.
12. Alghasham AA, Nahata MC, Clinical use of fluoroquinolones in children. Ann Pharmacother.
2000;34:347-59.

13. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58:S2936.

14. Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol
Infect Dis. 1991;10:267-74.
15. Sabharwal V and Marchant CD. Fluoroquinolone use in children. Pediatr Infect Dis J.
2006;25:257-8.
16. Mir N. Controlled multicenter study on chronic suppurative otitis media treated with topical
applications of ciprofloxacin 0.2% solution in single-dose containers or combination of
polymyxin B, neomycin, and hydrocortisone suspension. Otolaryngol Head Neck Surg.
2000;123:617-23.
17. Waldvogel FA. Use of quinolones for the treatment of osteomyelitis and septic arthritis. Rev
Infect Dis. 1989;11:S1259-63.
18. Lew DP, Waldvogel FA. Quinolones and osteomyelitis: State-of-the-art. Drugs. 1995;49:S100-1.
19. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic
disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with
acute pulmonary exacerbation. Pediatr Infect Dis J. 1997; 16:112-7.
20. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as
antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997; 16: 106-11.
21. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic
fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary
exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:97-105.
22. Richard DA, Nousia-Arvanitakis S, Solich V, Hampel BJ, Sommerauer B, Schaad UB. Oral
ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients:
comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and
magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis 1997;16:572-8.
23. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against
tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob
Agents Chemother. 2009;53:849-62.
24. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of
moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Animicrob Agents Chemother. 2004;48:780-2.

25. Mitnick CD, Shin SS, Seung KJ, Rich ML, et al. Comprehensive treatment of extensively drugresistant tuberculosis. N Engl J Med. 2008;359:563-74.
26. World Health Organization. Management of MDR-TB: a field guide: a companion document to
guidelines for programmatic management of drug-resistant tuberculosis: integrated management
of adolescent and adult illness. WHO/HTM/TB/2008.402.
27. Bergeron MG. The pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest
Med. 1989;12:20-7.
28. National Antimicrobial Resistance Surveillance Center, Thailand. Antibiogram 2007 (Available
at http://narst.dmsc.moph.go.th/ars/box/anti2007.pdf) Accessed on 8 Feb 2011.
29. Hooper DC, Strahilevitz J. Quinolones. In: Mandell, Douglas and BenettHs Principles and Practice
of Infectious Diseases, Seventh edition. Mandell GL, Bennett JE and Dolin R, eds. Churchill
Livingstone, Pennsylvania 2010:487-510.
30. Shlaes DM, Bass SN. Combination antimicrobial therapy. Pediatr Clin North Am. 1983;30:12134.
31. Rahal JJ Jr. Rationale for use of antimicrobial combinations in treatment of gram-negative
infections. A review of recent reviews. Am J Med. 1983;75:68-71.
32. Mesaros N, Nordmann P, Plsiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic
options at the turn of the new millennium. Clin Microbiol Infect. 2007;13:560-78.
33. Price EH, de Louvois J, Workman MR. Antibiotics for Salmonella meningitis in children. J
Antimicrob Chemother. 2000;46:653-5.
34. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr Allergy Asthma Rep.
2005;5:15-21.
35. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms
and cross-reactivity. Clin Exp Allergy. 2006;36:59-69.
36. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial
agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of
America. Clin Infect Dis. 2011;52:427-31.

 !##$%# Antibiotic and vaccine use in special circumstances

JK.(LMNKO) PQR STUMLMPVWXYYPZ PR[\J]O_
JK.L.`.QRJaTbV QbcYQRJNdT
\Jae_Y
JK.Lf.`bghJ_ UbijWk_LJLjOZ JJl_J
Lf.gXmJ QjKZWQbWdMn
JJl_J
YP.ofMj gXp_JbUYZ NlqlbrrM_ JJl_J
Lf.QYbP\JRV_ LjOZW_l_Jk JJl_J
&'(#)%*+,-,#)%* .

 quinolones  18 /: JK.L.`.QRJaTbV QbcYQRJNdT sra
L.U.YL.NdTQMgMUJ WXQJJtubdR